enoxaparin + clopidogrel + aspirin

This is a combination therapy consisting of three agents—enoxaparin, clopidogrel, and aspirin—used primarily in the management of acute coronary syndromes (ACS), including non-ST-elevation acute coronary syndromes (NSTE-ACS) and ST-elevation myocardial infarction (STEMI). - **Enoxaparin** is a low-molecular-weight heparin anticoagulant that potentiates antithrombin III to inhibit factor Xa and, to a lesser extent, factor IIa (thrombin), thereby preventing clot formation. - **Clopidogrel** is an oral antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, reducing platelet aggregation. - **Aspirin** is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 production and thus inhibiting platelet activation. The combination targets both the coagulation cascade and platelet aggregation pathways for comprehensive thromboprophylaxis in high-risk cardiovascular patients. This regimen has been shown to reduce major adverse cardiac events compared to standard therapies but increases bleeding risk[1][3][5].